Deferasirox Manufacturers
Deferasirox is an iron chelator belonging to a class of medications called Iron-Chelating agents. Deferasirox is the first oral medication approved by FDA for chronic iron overload in patients receiving blood transfusion for a prolonged use and this medication is also used to treat high levels of iron in people with certain blood disorders who actually do not require blood transfusion. Blood transfusion is often needed in few types of blood diseases such as anemia, sickle cell disease, which leads to additional iron that may build up in the body and cause problems such as diabetes, liver disease, heart failure etc, and deferasirox is used to eliminate the additional iron from the bloodstream and reduces the risk of these diseases.
Before using deferasirox, the risk of taking the drug must be weighed against the benefits it provides. It is always recommended to consult a physician before taking deferasirox as this medication may interact with other drugs or health problems.
Deferasirox is advised as a prescription product as well as generic prescription product. Manufacturers market deferasirox under the Brand name of Exjade, Jadenu. Deferasirox is available in a dosage form of tablet, granules, tablet for suspension in dosage strengths of 90 mg, 125 mg, 250 mg, 500 mg which is taken by mouth once daily on an empty stomach half an hour before meals. Deferasirox tablets are supplied as round, white, film coated tablets imprinted with the first letter of brand name and strength on one side and manufacturer name on the other side in a bottle of 30 tablets.
Deferasirox therapy should be considered only when a patient has proof of iron overload over a long-term blood transfusion, the recommended initial dose of deferasirox in transfusional iron overload patients with 2 years of age and older with estimated glomerular filtrate rate greater than 60 mL/min/1.73 m2 is 20 mg per kg body weight given orally once daily. The recommended initial dose of deferasirox in iron overload in non-transfusion-dependent thalassemia syndromes in patients with eGFR greater than 60 mL/min/1.73 m2 is 10 mg per kg body weight given orally once daily. Deferasirox Tablets are recommended to be stored at 25° C (77° F), in well closed containers with excursions permitted to 15° C to 30° C (59° F to 86° F) with protection from moisture.